This study assesses the cost-effectiveness of adding a sodium-glucose cotransporter 2 inhibitor versus switching to a glucagon-like peptide-1 receptor agonist in patients with diabetes on metformin and a dipeptidyl peptidase-4 inhibitor.
Julia F. Slejko, PhD
Advertisement
Articles by Julia F. Slejko, PhD
Formulary restrictions on brand name noninsulin antihyperglycemic drugs have little impact on treatment intensification patterns among low-income patients with diabetes in Medicare Part D.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Former USAID Health Chief Says Aid Cuts Are Costing Children's Lives
2
IDWeek Studies Tie RSV, Flu, and COVID-19 to Harm After Acute Illness
3
Merck, Moderna Cancer Vaccine Cuts Melanoma Recurrence Risk by 42%
4
It’s the Best of Times and Worst of Times for Cancer Care in Tampa
5